Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Oriel Therapeutics

Request full access

Specialty pharmaceutical company developing and commercializing products to improve respiratory care

Tarboro, United StatesFounded 2001Biotechnology

About Oriel Therapeutics

Oriel Therapeutics, established in 2001, operated as a specialty pharmaceutical firm with a strategic focus on the respiratory drug market. The company was co-founded by Dr. Paul J. Atkins, who brought extensive experience from his previous roles at GlaxoSmithKline, including the development of major respiratory products. His background in physical organic chemistry and deep knowledge of inhaled medicines were foundational to the company's direction.

The firm's primary business was the development of generic alternatives to brand-name medications for asthma and chronic obstructive pulmonary disease (COPD). Oriel's strategy centered on creating fully substitutable generic versions of key patented drugs, positioning itself to capitalize on the expiration of major patents in the substantial global market for asthma and COPD treatments. The company's operations were financed through venture capital, securing over $35 million in funding from investors including New Leaf Venture Partners, Thomas, McNerney & Partners, HealthCare Ventures, and CHL Medical Partners.

Oriel's core asset was its proprietary drug delivery platform. This included the innovative FreePath™ drug delivery technology and the Solis™ disposable dry powder inhaler (DPI). The technology was designed to overcome regulatory hurdles for generic inhaled medicines. A key patent covered the design of multi-dose dry powder packages that could be individually activated by a customized electrical input, causing them to vibrate for efficient aerosolization and drug dispersion. This system aimed to provide a more effective and user-friendly administration of inhaled therapies. The initial technology was licensed from the University of North Carolina at Chapel Hill.

A significant milestone in the company's history was its acquisition by Sandoz, the generics division of Novartis, in April 2010. Following the acquisition, Oriel was integrated as a separate development unit within Sandoz, allowing the larger firm to leverage Oriel's technology and product pipeline to enhance its position in the differentiated generics market. The terms of the acquisition were not publicly disclosed, but included potential milestone payments and sales royalties for Oriel's former owners.

Source: Dealroom company data

At a glance

Status
Closed
Open positions
None listed
Sector
Spinout
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VC✓Equity / VC Nov 2007 $27M $106M New Leaf Venture Partners —
SPINOUT✓Other financing Jan 2001 $0 — University of North Carolina at Chapel Hill —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Oriel Therapeutics website traffic

Latest recorded traffic for Oriel Therapeutics is 0 monthly website visits, down 100% over the last three months.

Latest monthly visits0 3-month web change-100%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Oriel Therapeutics in the Tarboro ecosystem

Live from Dealroom

The Oriel Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • New Leaf Venture Partners

Other known investors1 additional known investor

  • University of North Carolina at Chapel Hill
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Tarboro HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Oriel Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Oriel Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.